<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426228</url>
  </required_header>
  <id_info>
    <org_study_id>DSREC-11/2017_09</org_study_id>
    <nct_id>NCT03426228</nct_id>
  </id_info>
  <brief_title>In Vitro Fertilization Impact on Metabolic Parameters</brief_title>
  <acronym>IVF</acronym>
  <official_title>Effects of Fertility Drugs on Glucose Homeostasis and Other Metabolic Parameters on Patients Undergoing In Vitro Fertilization (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fakih IVF Fertility Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sharjah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Warwick</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A quantitative prospective cohort study will be conducted, where blood samples will be&#xD;
      collected at different timings during the IVF protocol, to assess the impact of fertility&#xD;
      medications on metabolic parameters of patients undergoing IVF treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous factors predispose women to develop pregnancy-related complications, these include&#xD;
      gestational diabetes (GDM), pre-pregnancy obesity, advanced maternal age (&gt; 35 years) and&#xD;
      gestational age, abnormal weight gain during pregnancy, family history of diabetes, PCOS and&#xD;
      low parity. Evidenced-based studies reported that women with PCOS have a significantly higher&#xD;
      risk of developing GDM compared with women without PCOS, independently of the obesity factor;&#xD;
      this risk is higher when both factors coexist.&#xD;
&#xD;
      Given the known effect of reproductive hormones on weight-gain, controversies still exist on&#xD;
      whether ART predispose women to more adverse obstetric outcomes compared to normal pregnancy.&#xD;
      ART describes different procedures to help women become pregnant, with In Vitro Fertilization&#xD;
      (IVF) being the most commonly performed. It has been demonstrated that IVF is associated with&#xD;
      glucose intolerance in mice and it will be interesting to determine whether this physiologic&#xD;
      phenomenon is also altered by IVF medication (such as estrogen and progesterone) in humans.&#xD;
      While some studies reported that singleton pregnancies conceived by ART (IVF or ovulation&#xD;
      induction) were strongly associated with GDM compared to spontaneous conceptions, other&#xD;
      studies did not find significant differences in the risk of GDM. Increased GDM risk presented&#xD;
      with IVF can be associated with prenatal obesity or secondary to maternal PCOS condition. The&#xD;
      former studies did not specify the body mass index (BMI) and the medical history of&#xD;
      participants undergoing IVF, such as the presence of PCOS. Due to limited available data, we&#xD;
      still cannot distinguish whether these adverse pregnancy outcomes are due to the pre-existing&#xD;
      conditions such as PCOS, or are secondary to the IVF therapy itself.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">January 5, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Short-term Effect of Fertility Medications on Glucose Homeostasis and Insulin Resistance in Patients Undergoing IVF Treatment</measure>
    <time_frame>12 weeks of pregnancy</time_frame>
    <description>Participants who experience an abnormal increase in fasting glucose (&gt;110) and A1C (&gt;5.7) will be identified post-treatment. Also, for those previously known to be insulin-resistant, HOMA ratio will help identifying whether the treatment worsens or has no effect on their insulin resistance state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Fertility Medications on Lipids Profile</measure>
    <time_frame>12 weeks of pregnancy</time_frame>
    <description>Lipid profile will be measured before and after treatment; participants experiencing hypercholesterolemia post-treatment will be consulted by a dietitian to help them better manage the condition during their pregnancy (total chol, LDL and triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Fertility Medications on Thyroid Function</measure>
    <time_frame>12 weeks of pregnancy</time_frame>
    <description>TSH level will be measured pre- and post-IVF. Early diagnosis of thyroid dysfunction will be closely monitored with frequent repetitions of blood test, especially during the first trimester.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Long-term Effect of Fertility Medications in Relation to Maternal and Fetal Outcomes</measure>
    <time_frame>9 months of pregnancy</time_frame>
    <description>Early management and/control of metabolic-related adverse outcomes in relation to IVF treatment will prevent GDM by for instance glucophage administration or regular blood test of TSH for participants reported to be at higher risk of thyroid dysfunction.</description>
  </other_outcome>
  <enrollment type="Actual">344</enrollment>
  <condition>GDM</condition>
  <condition>Insulin Resistance</condition>
  <condition>Glucose Intolerance</condition>
  <condition>PCOS</condition>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HbA1C</intervention_name>
    <description>After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:&#xD;
At baseline (second day of the menstrual period)&#xD;
Triggering phase (post-egg retrieval procedure)&#xD;
Embryo transfer phase (post-transfer procedure)&#xD;
Week 4 (positive bHCG)&#xD;
4. Week 8 of pregnancy</description>
    <other_name>Lipid profile</other_name>
    <other_name>Hormonal profile: FSH, LH, progesterone, estrogen,Beta-HCG</other_name>
    <other_name>Serum Insulin level</other_name>
    <other_name>Fasting Glucose level</other_name>
    <other_name>Thyroid-Stimulating Hormone</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A convenience sample from adult women of &lt; 39 years of age undergoing fresh IVF treatment&#xD;
        at Fakih IVF Clinic in Dubai will be chosen. Participants who will fulfill the inclusion&#xD;
        criteria will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Any patient presenting to us for fresh IVF with the following:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting with or without PCOS&#xD;
&#xD;
          -  Presenting with structural or mechanical infertility, such as fallopian tube&#xD;
             obstruction, endometriosis, fibroids&#xD;
&#xD;
          -  Presenting with male factor&#xD;
&#xD;
          -  Presenting with or without insulin resistance&#xD;
&#xD;
          -  Combination of more than one of the listed above criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-diabetes or diabetes patients (confirmed by impaired or abnormal OGTT)&#xD;
&#xD;
          -  Age above 39 years of age&#xD;
&#xD;
          -  Taking glucose-lowering meds, such as metformin or janumet.&#xD;
&#xD;
          -  Taking corticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>We will have two main groups of: Obese (BMI: 30-38) and non-obese (BMI: 18.5-29.9) women with the following criteria</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayla Coussa, Dietitian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakih IVF Dubai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakih IVF</name>
      <address>
        <city>Dubai</city>
        <zip>72960</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <reference>
    <citation>Coussa A, Hasan HA, Barber TM. Effects of in vitro fertilization (IVF) therapies on metabolic, endocrine and inflammatory status in IVF-conceived pregnancy. Clin Endocrinol (Oxf). 2020 Dec;93(6):705-712. doi: 10.1111/cen.14270. Epub 2020 Jul 9.</citation>
    <PMID>32578220</PMID>
  </reference>
  <results_reference>
    <citation>Coussa A, Hasan HA, Barber TM. Impact of contraception and IVF hormones on metabolic, endocrine, and inflammatory status. J Assist Reprod Genet. 2020 Jun;37(6):1267-1272. doi: 10.1007/s10815-020-01756-z. Epub 2020 Mar 25. Review.</citation>
    <PMID>32215823</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>June 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2021</results_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warwick</investigator_affiliation>
    <investigator_full_name>Ayla Coussa</investigator_full_name>
    <investigator_title>MSc.</investigator_title>
  </responsible_party>
  <keyword>IVF, Glucose Homeostasis, Metabolic Parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All the study information will be kept confidential. Patients' names will not be identified in any publication or presentation of the study findings. Only groups' results will be reported.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After conducting data collection and analysis the results will be available upon official publication.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent committee. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03426228/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03426228/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03426228/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>702screened --&gt;673eligible to start IVF--&gt;359 had embryo transfer --&gt;191clinically confirmed pregnant+158 negative β-HCG+10 biochem pregnancy--&gt; 64drop-outs+10 miscarriage--&gt; Completed study and included in data: 158 pregnant+117 non-pregnant women</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Non-Pregnant</title>
          <description>Negative BHCG at 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Pregnant</title>
          <description>Positive BHCG at 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-Pregnant</title>
          <description>Negative BHCG at 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Pregnant</title>
          <description>Positive BHCG at 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="158"/>
            <count group_id="B3" value="275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" lower_limit="25.5" upper_limit="39.5"/>
                    <measurement group_id="B2" value="32" lower_limit="25" upper_limit="39"/>
                    <measurement group_id="B3" value="32.3" lower_limit="25" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="158"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>At 4 weeks, 191 were confirmed pregnant and 158 were non pregnant (negative BHCG). At 12weeks, 117 non-pregnants and 158 pregnants completed the study and analyzed (74 women excluded from data and attributed to drop-outs + those who travelled without completing the 12-week blood test).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Short-term Effect of Fertility Medications on Glucose Homeostasis and Insulin Resistance in Patients Undergoing IVF Treatment</title>
        <description>Participants who experience an abnormal increase in fasting glucose (&gt;110) and A1C (&gt;5.7) will be identified post-treatment. Also, for those previously known to be insulin-resistant, HOMA ratio will help identifying whether the treatment worsens or has no effect on their insulin resistance state.</description>
        <time_frame>12 weeks of pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Pregnant</title>
            <description>Negative BHCG at 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pregnant</title>
            <description>Positive BHCG at 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Effect of Fertility Medications on Glucose Homeostasis and Insulin Resistance in Patients Undergoing IVF Treatment</title>
          <description>Participants who experience an abnormal increase in fasting glucose (&gt;110) and A1C (&gt;5.7) will be identified post-treatment. Also, for those previously known to be insulin-resistant, HOMA ratio will help identifying whether the treatment worsens or has no effect on their insulin resistance state.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.62" lower_limit="79.3" upper_limit="95.9"/>
                    <measurement group_id="O2" value="82.19" lower_limit="75" upper_limit="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin, fasting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.37" lower_limit="4.00" upper_limit="14.8"/>
                    <measurement group_id="O2" value="9.45" lower_limit="2.5" upper_limit="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Fertility Medications on Lipids Profile</title>
        <description>Lipid profile will be measured before and after treatment; participants experiencing hypercholesterolemia post-treatment will be consulted by a dietitian to help them better manage the condition during their pregnancy (total chol, LDL and triglycerides)</description>
        <time_frame>12 weeks of pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnant</title>
            <description>Positive BHCG at 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Non-pregnant</title>
            <description>Negative BHCG at 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Fertility Medications on Lipids Profile</title>
          <description>Lipid profile will be measured before and after treatment; participants experiencing hypercholesterolemia post-treatment will be consulted by a dietitian to help them better manage the condition during their pregnancy (total chol, LDL and triglycerides)</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.5" lower_limit="155.15" upper_limit="243.9"/>
                    <measurement group_id="O2" value="174.9" lower_limit="126.9" upper_limit="222.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Fertility Medications on Thyroid Function</title>
        <description>TSH level will be measured pre- and post-IVF. Early diagnosis of thyroid dysfunction will be closely monitored with frequent repetitions of blood test, especially during the first trimester.</description>
        <time_frame>12 weeks of pregnancy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregnant</title>
            <description>Positive BHCG at 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Non-pregnant</title>
            <description>Negative BHCG at 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Fertility Medications on Thyroid Function</title>
          <description>TSH level will be measured pre- and post-IVF. Early diagnosis of thyroid dysfunction will be closely monitored with frequent repetitions of blood test, especially during the first trimester.</description>
          <units>μIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" lower_limit="0.26" upper_limit="2.46"/>
                    <measurement group_id="O2" value="1.80" lower_limit="0.75" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Long-term Effect of Fertility Medications in Relation to Maternal and Fetal Outcomes</title>
        <description>Early management and/control of metabolic-related adverse outcomes in relation to IVF treatment will prevent GDM by for instance glucophage administration or regular blood test of TSH for participants reported to be at higher risk of thyroid dysfunction.</description>
        <time_frame>9 months of pregnancy</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <desc>Study is observational and non-experimental. No invasive procedures were used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Non-Pregnant</title>
          <description>Negative BHCG at 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Pregnant</title>
          <description>Positive BHCG at 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="158"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ayla Coussa</name_or_title>
      <organization>Fakih IVF</organization>
      <phone>+971501403866</phone>
      <email>A.coussa@warwick.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

